Welcome, Guest. Please login or register.
March 02, 2021, 12:50:47 am

Login with username, password and session length

  • Total Posts: 55034
  • Total Topics: 4830
  • Online Today: 40
  • Online Ever: 1314
  • (June 22, 2016, 05:23:42 am)
Users Online
Users: 0
Guests: 33
Total: 33


Welcome to the Hep Forums, a round-the-clock discussion area for people who have Hepatitis B, C or a co-infection, their friends and family and others with questions about hepatitis and liver health. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Hep Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: In People With Hep B, Statin Use Is Tied to Reduced Liver Cancer Risk  (Read 1096 times)

0 Members and 1 Guest are viewing this topic.

Offline Hep Editors

  • Member
  • Posts: 784
    • Hep Mag
The use of cholesterol-lowering statin medications among people with hepatitis B virus (HBV) is independently associated with a lower risk of hepatocellular carcinoma (HCC), the most common form of liver cancer, Healio reports.

Publishing their findings in Hepatology, a research team led by Myung Ji Goh, MD, of Sungkyunkwan University School of Medicine in South Korea, analyzed data on 7,713 people with HBV, including 713 people who took statins and 7,000 who did not.

The cohort members were defined as using statins if they took at least 28 cumulative daily doses during the study’s follow-up period.



© 2021 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.